Mediclinic released an interim trading update on 17 October. The statement indicated constrained trading conditions and regulatory headwinds. This translated into lower than expected earnings for its Swiss unit specifically, which contributes the majority of the group’s profits. View the video for an explanation on why we are taking a cautious approach to this share.
